Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Price to FCFE (P/FCFE)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Gilead Sciences Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss) attributable to Gilead1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2011 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 3, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Gilead Sciences Inc. Annual Report.
The company's share price exhibited a general upward trend from 2006 to 2015, rising from $15.03 to a peak of $104.43 in early 2015. After this peak, the share price experienced some volatility, declining to $62.79 by 2021, then recovering to $83.50 in 2023, before fluctuating again to reach $114.31 by early 2025. This pattern suggests periods of strong market optimism interspersed with corrections.
Earnings per share (EPS) demonstrated variability over the years. Starting at $0.44 in 2006, EPS showed a negative value in 2007 (-$0.64), followed by a recovery and gradual increase through 2011, peaking sharply at $13.25 in 2015. After this peak, the EPS dropped considerably to $3.53 in 2018 and fluctuated around the mid-single digits until 2024, with a notable low of $0.10 in 2021 and another decline to $0.39 projected for 2025. These fluctuations indicate volatility in the company's profitability, including some periods of significant earnings growth and occasional steep declines.
The price-to-earnings (P/E) ratio exhibited considerable instability. It began at 34.15 in 2006, declined to around the teens and twenties in the following years, and spiked to very high levels during years where EPS were low or negative, such as an extreme P/E of 641.48 in 2021 and 296.57 projected for 2025. The large spikes in the P/E ratio correspond to very low or near-zero EPS values, signaling elevated market price relative to earnings during periods of diminished profitability.
- Share Price Trend:
- Overall growth with marked volatility post-2015, fluctuating between mid $60s and low $100s in recent years.
- EPS Trend:
- Initial growth disrupted by negative earnings in 2007, substantial peak around 2015, followed by a downward trend and volatility in subsequent years with some sharp earnings declines.
- P/E Ratio Trend:
- Fluctuated in alignment with EPS changes; extreme spikes occurred during periods of very low or negative earnings, indicating high valuation relative to earnings during such times.
The data reflects a company experiencing cycles of robust growth and profitability along with phases of earnings pressure and valuation variability. The sharp EPS peaks and troughs, coupled with the matching P/E volatility, highlight earnings sensitivity in the market's assessment of the company's valuation over the analyzed period.
Comparison to Competitors
Gilead Sciences Inc., P/E, long-term trends, comparison to competitors
| Gilead Sciences Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | ||||||||||||
| Feb 23, 2024 | ||||||||||||
| Feb 22, 2023 | ||||||||||||
| Feb 23, 2022 | ||||||||||||
| Feb 25, 2021 | ||||||||||||
| Feb 25, 2020 | ||||||||||||
| Feb 26, 2019 | ||||||||||||
| Feb 27, 2018 | ||||||||||||
| Feb 27, 2017 | ||||||||||||
| Feb 24, 2016 | ||||||||||||
| Feb 25, 2015 | ||||||||||||
| Feb 25, 2014 | ||||||||||||
| Feb 27, 2013 | ||||||||||||
| Feb 23, 2012 | ||||||||||||
| Feb 28, 2011 | ||||||||||||
| Mar 1, 2010 | ||||||||||||
| Feb 27, 2009 | ||||||||||||
| Feb 27, 2008 | ||||||||||||
| Feb 27, 2007 | ||||||||||||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Gilead Sciences Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Gilead Sciences Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 28, 2025 | ||
| Feb 23, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 25, 2021 | ||
| Feb 25, 2020 | ||
| Feb 26, 2019 | ||
| Feb 27, 2018 | ||
| Feb 27, 2017 | ||
| Feb 24, 2016 | ||
| Feb 25, 2015 | ||
| Feb 25, 2014 | ||
| Feb 27, 2013 | ||
| Feb 23, 2012 | ||
| Feb 28, 2011 | ||
| Mar 1, 2010 | ||
| Feb 27, 2009 | ||
| Feb 27, 2008 | ||
| Feb 27, 2007 | ||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Gilead Sciences Inc., P/E, long-term trends, comparison to industry (health care)
| Gilead Sciences Inc. | Health Care | |
|---|---|---|
| Feb 28, 2025 | ||
| Feb 23, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 25, 2021 | ||
| Feb 25, 2020 | ||
| Feb 26, 2019 | ||
| Feb 27, 2018 | ||
| Feb 27, 2017 | ||
| Feb 24, 2016 | ||
| Feb 25, 2015 | ||
| Feb 25, 2014 | ||
| Feb 27, 2013 | ||
| Feb 23, 2012 | ||
| Feb 28, 2011 | ||
| Mar 1, 2010 | ||
| Feb 27, 2009 | ||
| Feb 27, 2008 | ||
| Feb 27, 2007 | ||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).